Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis

The Lancet Global Health

Volumn 5, Issue 12, 2017, Pages e1235-e1248

  Tickell, Kirkby D ^a   Brander, Rebecca L ^a   Atlas, Hannah E ^a   Pernica, Jeffrey M ^c   Walson, Judd L ^a,b   Pavlinac, Patricia B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; PIVMECILLINAM; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ARTICLE; BINOMIAL DISTRIBUTION; CLINICAL EFFECTIVENESS; DIAGNOSTIC VALUE; DIARRHEA; DYSENTERY; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; SENSITIVITY AND SPECIFICITY; SHIGELLOSIS; SYSTEMATIC REVIEW; CHILD; ISOLATION AND PURIFICATION; MORTALITY; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHIGELLA; STANDARDS; WORLD HEALTH ORGANIZATION;

ANTI-BACTERIAL AGENTS; CHILD; DIARRHEA; DYSENTERY, BACILLARY; FLUOROQUINOLONES; GUIDELINE ADHERENCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHIGELLA; WORLD HEALTH ORGANIZATION;

EID: 85033717893     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(17)30392-3     Document Type: Article

References (71)

1. Kotloff, KL, Nataro, JP, Blackwelder, WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382 (2013), 209–222.
2. Liu, J, Platts-Mills, JA, Juma, J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet 388 (2016), 1291–1301.
3. O'Reilly, CE, Jaron, P, Ochieng, B, et al. Risk factors for death among children less than 5 years old hospitalized with diarrhea in rural western Kenya, 2005–2007: a cohort study. PLoS Med, 9, 2012, e1001256.
4. Islam, SS, Shahid, NS, Morbidity and mortality in a diarrhoeal diseases hospital in Bangladesh. Trans R Soc Trop Med Hyg 80 (1986), 748–752.
5. Afroze, F, Ahmed, T, Sarmin, M, et al. Risk factors and outcome of Shigella encephalopathy in Bangladeshi children. PLoS Negl Trop Dis, 11, 2017, e0005561.
6. Khan, WA, Griffiths, JK, Bennish, ML, Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS One, 8, 2013, e64097.
7. WHO. The treatment of diarrhoea: a manual for physicians and other senior health workers. 2005, World Health Organization, Geneva.
8. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005, World Health Organization, Geneva.
9. Ronsmans, C, Bennish, ML, Wierzba, T, Diagnosis and management of dysentery by community health workers. Lancet 2 (1988), 552–555.
10. Bennish, ML, Harris, JR, Wojtyniak, BJ, Struelens, M, Death in shigellosis: incidence and risk factors in hospitalized patients. J Infect Dis 161 (1990), 500–506.
11. Prince Christopher, RH, David, KV, John, SM, Sankarapandian, V, Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev, 1, 2010 CD006784.
12. Livio, S, Strockbine, NA, Panchalingam, S, et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis 59 (2014), 933–941.
13. von Seidlein, L, Kim, DR, Ali, M, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med, 3, 2006, e353.
14. Khatun, F, Faruque, AS, Koeck, JL, et al. Changing species distribution and antimicrobial susceptibility pattern of Shigella over a 29-year period (1980–2008). Epidemiol Infect 139 (2011), 446–452.
15. Atkins, D, Best, D, Briss, PA, et al. Grading quality of evidence and strength of recommendations. BMJ, 328, 2004, 1490.
16. Whiting, P, Rutjes, A, Johannes, B, Bossuyt, PM, Kleijnen, J, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 10 (2003), 3–25.
17. Dutta, P, Mitra, U, Rasaily, R, et al. Assessing the cause of in-patients pediatric diarrheal deaths: an analysis of hospital records. Indian Pediatr 32 (1995), 313–321.
18. Pernica, JM, Steenhoff, AP, Welch, H, et al. Correlation of clinical outcomes with multiplex molecular testing of stool from children admitted to hospital with gastroenteritis in Botswana. J Pediatric Infect Dis Soc 5 (2016), 312–318.
19. Teka, T, Faruque, AS, Fuchs, GJ, Risk factors for deaths in under-age-five children attending a diarrhoea treatment centre. Acta Paediatr 85 (1996), 1070–1075.
20. Uysal, G, Sokmen, A, Vidinlisan, S, Clinical risk factors for fatal diarrhea in hospitalized children. Indian J Pediatr 67 (2000), 329–333.
21. van den Broek, JM, Roy, SK, Khan, WA, et al. Risk factors for mortality due to shigellosis: a case-control study among severely-malnourished children in Bangladesh. J Health Popul Nutr 23 (2005), 259–265.
22. Pavlinac, PB, Denno, DM, John-Stewart, GC, et al. Failure of Syndrome-based diarrhea management guidelines to detect Shigella infections in Kenyan children. J Pediatric Infect Dis Soc 5 (2016), 366–374.
23. Aggarwal, P, Uppal, B, Ghosh, R, Krishna Prakash, S, Chakravarti, A, Rajeshwari, K, True prevalence of shigellosis in Indian children with acute gastroenteritis: have we been missing the diagnosis?. J Res Health Sci 16 (2016), 11–16.
24. Eseigbe, EE, Iriah, S, Ibok, S, et al. Bacterial isolates from the stools of children aged less than 5 years with acute diarrhea in Kaduna, Northwestern Nigeria. Ann Trop Med Public Health 6 (2013), 452–455.
25. Hegde, ST, Benoit, S, Lopez, B, et al. Burden of laboratory-confirmed shigellosis infections in guatemala 2007–2012: results from a population-based surveillance system. Am J Trop Med Hyg, 89, 2013, 453.
26. Dooki, MRE, Rajabnia, R, Sawadkohi, RB, Gatabi, ZM, Poornasrollah, M, Mirzapour, M, Bacterial entropathogens and antimicrobial susceptibility in children with acute diarrhea in Babol, Iran. Caspian J Intern Med 5 (2014), 30–34.
27. Debas, G, Kibret, M, Biadglegne, F, Abera, B, Prevalence and antimicrobial susceptibility patterns of shigella species at Felege Hiwot Referral Hospital, Northwest Ethiopia. Ethiop Med J 49 (2011), 249–256.
28. El-Shabrawi, M, Salem, M, Abou-Zekri, M, et al. The burden of different pathogens in acute diarrhoeal episodes among a cohort of Egyptian children less than five years old. Prz Gastroenterol 10 (2015), 173–180.
29. Jafari, F, Shokrzadeh, L, Hamidian, M, Salmanzadeh-Ahrabi, S, Zali, MR, Acute diarrhea due to enteropathogenic bacteria in patients at hospitals in Tehran. Jpn J Infect Dis 61 (2008), 269–273.
30. Ozmert, EN, Orun, E, Sengelen, M, Yalcin, SS, Yurdakok, K, Gur, D, Sensitivity and specificity of bloody diarrhea in shigella gastroenteritis. Turk J Pediatr 52 (2010), 488–490.
31. Suwatano, O, Acute diarrhea in under five-year-old children admitted to King Mongkut Prachomklao Hospital, Phetchaburi province. J Med Assoc Thai 80 (1997), 26–33.
32. Youssef, M, Shurman, A, Bougnoux, M, Rawashdeh, M, Bretagne, S, Strockbine, N, Bacterial, viral and parasitic enteric pathogens associated with acute diarrhea in hospitalized children from northern Jordan. FEMS Immunol Med Microbiol 28 (2000), 257–263.
33. Nakano, T, Kamiya, H, Matsubayashi, N, Watanabe, M, Sakurai, M, Honda, T, Diagnosis of bacterial enteric infections in children in Zambia. Acta Paediatr Jpn 40 (1998), 259–263.
34. Mathan, VI, Mathan, MM, Intestinal manifestations of invasive diarrheas and their diagnosis. Rev Infect Dis 13:suppl 4 (1991), S311–S313.
35. Sobel, J, Gomes, TAT, Ramos, RTS, et al. Pathogen-specific risk factors and protective factors for acute diarrheal illness in children aged 12–59 months in Sao Paulo, Brazil. Clin Infect Dis 38 (2004), 1545–1551.
36. Ahmed, F, Clemens, JD, Rao, MR, Ansaruzzaman, M, Haque, E, Epidemiology of shigellosis among children exposed to cases of Shigella dysentery: a multivariate assessment. Am J Trop Med Hyg 56 (1997), 258–264.
37. Kagalwalla, AF, Khan, SN, Kagalwalla, YA, Alola, S, Yaish, H, Childhood shigellosis in Saudi Arabia. Pediatr Infect Dis J 11 (1992), 215–219.
38. Dutta, P, Bhattacharya, SK, Sen, D, et al. Shigellosis in children: a prospective hospital based study. Indian Pediatr 29 (1992), 1125–1130.
39. Echeverria, P, Sethabutr, O, Pitarangsi, C, Microbiology and diagnosis of infections with Shigella and enteroinvasive Escherichia coli. Rev Infect Dis 13:suppl 4 (1991), S220–S225.
40. Moalla, H, Fendri, C, Etiology of acute diarrhea in children. Tunis Med 72 (1994), 25–28.
41. Huskins, WC, Griffiths, JK, Faruque, AS, Bennish, ML, Shigellosis in neonates and young infants. J Pediatr 125 (1994), 14–22.
42. Stoll, BJ, Glass, RI, Huq, MI, Khan, MU, Banu, H, Holt, J, Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 146 (1982), 177–183.
43. Mo-Suwan, L, Varavithya, W, Clinical profile of diarrhoea at Ramathibodi Hospital during 1977. Southeast Asian J Trop Med Public Health 10 (1979), 142–146.
44. WHO. WHO model lists of essential medicines. 2017, World Health Organization, Geneva http://www.who.int/medicines/publications/essentialmedicines/en/ (accessed Oct 17, 2017).
45. Alam, AN, Islam, MR, Hossain, MS, Mahalanabis, D, Hye, HK, Comparison of pivmecillinam and nalidixic acid in the treatment of acute shigellosis in children. Scand J Gastroenterol 29 (1994), 313–317.
46. Basualdo, W, Arbo, A, Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 22 (2003), 374–377.
47. Bhattacharya, K, Bhattacharya, MK, Dutta, D, et al. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr 86 (1997), 319–320.
48. Dutta, P, Sett, A, Sarkar, A, et al. Comparative efficacy of furazolidone and nalidixic acid in the empirical treatment of acute invasive diarrhea: randomized clinical trial. Indian Pediatr 32 (1995), 13–19.
49. Gilman, RH, Koster, F, Islam, S, McLaughlin, J, Rahaman, MM, Randomized trial of high- and low-dose ampicillin therapy for treatment of severe dysentery due to Shigella dysenteriae type 1. Antimicrob Agents Chemother 17 (1980), 402–405.
50. Gilman, RH, Spira, W, Rabbani, H, Ahmed, W, Islam, A, Rahaman, MM, Single-dose ampicillin therapy for severe shigellosis in Bangladesh. J Infect Dis 143 (1981), 164–169.
51. Helvaci, M, Bektaslar, D, Ozkaya, B, Yaprak, I, Umurtak, B, Ertugrul, A, Comparative efficacy of cefixime and ampicillin–sulbactam in shigellosis in children. Acta Paediatr Jpn 40 (1998), 131–134.
52. Islam, MR, Alam, AN, Hossain, MS, Mahalanabis, D, Hye, HK, Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children. J Trop Pediatr 40 (1994), 320–325.
53. Moolasart, P, Eampokalap, B, Ratanasrithong, M, Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children. Southeast Asian J Trop Med Public Health 30 (1999), 764–769.
54. Prado Camacho, JL, A comparison of furazolidone and ampicillin in the treatment of invasive diarrhea. Scand J Gastroenterol Suppl 169 (1989), 54–59.
55. Prado, D, López, E, Liu, H, et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 11 (1992), 644–647.
56. Prado, D, Liu, H, Velasquez, T, Cleary, TG, Comparative efficacy of pivmecillinam and cotrimoxazole in acute shigellosis in children. Scand J Infect Dis 25 (1993), 713–719.
57. Rodriguez, RS, Chavez, AZ, Galindo, E, A randomized, controlled, single-blind study comparing furazolidone with trimethoprim–sulfamethoxazole in the empirical treatment of acute invasive diarrhea. Scand J Gastroenterol Suppl 169 (1989), 47–53.
58. Salam, MA, Bennish, ML, Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 113 (1988), 901–907.
59. Salam, MA, Dhar, U, Khan, WA, Bennish, ML, Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 352 (1998), 522–527.
60. Taylor, DN, Blaser, MJ, Echeverria, P, Pitarangsi, C, Bodhidatta, L, Wang, WL, Erythromycin-resistant Campylobacter infections in Thailand. Antimicrob Agents Chemother 31 (1987), 438–442.
61. Vinh, H, Wain, J, Chinh, MT, et al. Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg 94 (2000), 323–326.
62. Vinh, H, Anh, VTC, Anh, ND, et al. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS Negl Trop Dis, 5, 2011, e1264.
63. Yunus, M, Mizanur Rahman, AS, Farooque, AS, Glass, RI, Clinical trial of ampicillin v. trimethoprim-sulphamethoxazole in the treatment of Shigella dysentery. J Trop Med Hyg 85 (1982), 195–199.
64. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 21 (2002), 1136–1141.
65. de Widerspach-Thor, A, d'Alteroche, L, Rault, A, Thuan, JF, Masseron, T, Hovette, P, Predictive factors of mortality in severe shigellosis. Med Trop, 62, 2002, 101.
66. Zaman, K, Yunus, M, Baqui, AH, Hossain, KM, Surveillance of shigellosis in rural Bangladesh: a 10 years review. J Pak Med Assoc 41 (1991), 75–78.
67. Liu, J, Kabir, F, Manneh, J, et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect Dis 14 (2014), 716–724.
68. Keddy, KH, Sooka, A, Crowther-Gibson, P, et al. Systemic shigellosis in South Africa. Clin Infect Dis 54 (2012), 1448–1454.
69. Bennish, ML, Potentially lethal complications of shigellosis. Rev Infect Dis 13:suppl 4 (1991), S319–S324.
70. Gu, B, Zhou, M, Ke, X, et al. Comparison of resistance to third-generation cephalosporins in Shigella between Europe–America and Asia–Africa from 1998 to 2012. Epidemiol Infect 143 (2015), 2687–2699.
71. Bennish, ML, Wojtyniak, BJ, Mortality due to shigellosis: community and hospital data. Rev Infect Dis 13:suppl 4 (1991), S245–S251.